Palvella Therapeutics Engages with Investors at Growth Conference
WAYNE, Pa. — Palvella Therapeutics, Inc. (Nasdaq: PVLA), a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for rare genetic skin diseases, announces that its Founder and CEO, Wes Kaupinen, will participate in an engaging fireside chat at the Canaccord Genuity 45th Annual Growth Conference.
Importance of the Conference
This significant event offers Palvella a platform to share its innovative approaches and the latest advancements in treatment options for patients who currently lack effective therapies approved by the FDA. The fireside chat is scheduled for a future date, showcasing Palvella's commitment to transparency and investor relations.
Live Webcast and Access
For those interested in following the discussion, a live webcast of the chat will be accessible through Palvella's official website in the Events and Presentations section. Additionally, an archived version of the presentation will also be available for approximately 90 days afterwards, allowing stakeholders and interested parties to catch up on the insights shared during the event.
About Palvella Therapeutics
Palvella Therapeutics is leading the charge in clinical-stage biopharmaceutical development, particularly focusing on rare genetic skin diseases that remain unaddressed by existing FDA-approved treatments. The company prides itself on its diverse development pipeline, which utilizes its patented QTORIN™ platform aimed at tackling these challenging conditions.
Current Pipeline and Research Trials
Among its most promising candidates is QTORIN™ 3.9% rapamycin anhydrous gel, aimed at treating microcystic lymphatic malformations. Currently in the Phase 3 SELVA clinical trial, QTORIN™ is also under investigation in the Phase 2 TOIVA clinical trial for managing cutaneous venous malformations. Both trials underscore Palvella's commitment to finding effective solutions for complicated medical issues.
Engaging with the Community
Palvella is not only focused on drug development, but also on fostering a community of support around those affected by rare diseases. The company actively seeks feedback and promotes awareness initiatives to ensure patients receive the best possible advocacy and treatment options.
Future Aspirations
Looking ahead, Palvella Therapeutics envisions expanding its research endeavors to revolutionize the landscape of treatments available for rare genetic conditions. With hopes of paving the way for future innovations, the company invites potential collaborators and investors to join them on this journey toward change and advancement.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
Frequently Asked Questions
What is the focus of Palvella Therapeutics?
Palvella Therapeutics concentrates on developing therapies for rare genetic skin diseases that currently lack FDA-approved treatments.
Who is presenting at the conference?
Wes Kaupinen, the Founder and CEO of Palvella, is scheduled to participate in the fireside chat at the conference.
Where can I access the live webcast?
The live webcast and future presentations can be accessed on Palvella's official website under the Events and Presentations section.
What is QTORIN™ rapamycin?
QTORIN™ rapamycin is Palvella’s lead product candidate aimed at treating microcystic lymphatic malformations and is currently undergoing clinical trials.
How does Palvella engage with the community?
Palvella actively promotes awareness initiatives and seeks community feedback to better advocate for patients suffering from rare diseases.
